UNSPSC 51263162: Esmolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V05260LC8D, chemically known as benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester but more generally known as esmolol hydrochloride, which bears US NIH Compound Identifier 59768. European Medicines Agency schedules Esmolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01959MIG.

UNSPSC 51263162 Esmolol hydrochloride is a Commodity code that in state and local procurement practice covers pharmaceutical products, though the recent opportunities tagged to this code show limited direct alignment with esmolol specifically. Seminole County, Florida's IFB60459723LAS solicitation seeks naloxone and drug deactivation systems for community health support, while the Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription fulfillment models for state pharmacy benefit programs — both pharmaceutical-adjacent but neither explicitly esmolol procurement. The issuing bodies show diversity across county health departments and state health agencies; Seminole County Community Health Building is the operational delivery site for the Florida opportunity, and Texas HHS Commission drives the exploratory Texas initiative. Neither opportunity specifies set-aside designations or budget ranges at the point of posting.

Recent activity centers on Florida and Texas. The Seminole County IFB (due July 26, 2023) requires annual volumes of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, fixed-fee pricing, two-year initial term with one-year renewal option, and FEMA potential funding with attendant federal compliance requirements. The Texas RFI (response due April 3, 2026) is exploratory, seeking vendor capabilities for direct pharmaceutical contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal evaluation criteria or award value specified. Both solicitations require E-Verify compliance and drug-free workplace certification. The code shows sparse recent activity under its nominal scope; state and local procurement offices have tagged pharmaceutical-related opportunities here, but esmolol hydrochloride specifically does not appear in either recent opportunity.